Massimiliano Camilli: Mechanistic Insights Into Cardiovascular Risk Across Androgen Deprivation Therapies
Massimiliano Camilli, Member of the Atrial Disorders Committee of the Heart Failure Association of the ESC at European Society of Cardiology, shared a post on LinkedIn about a recent article by Antonia Beitzen-Heineke et al, published in JACC: CardioOncology, adding:
“Why might cardiovascular risk differ across androgen deprivation therapies?
A new prospective study in JACC: CardioOncology provides interesting mechanistic insights into the cardiovascular effects of androgen deprivation therapy in patients with prostate cancer.
Patients with prostate cancer already showed a heightened platelet activation and thromboinflammatory profile compared with healthy controls.
Importantly, the two ADT strategies appeared to have different effects:
- Leuprolide was associated with further increases in platelet reactivity across multiple agonist pathways.
- Relugolix, in contrast, did not increase platelet activation and was associated with reduced arachidonic acid–induced P-selectin and CD40 expression, alongside down-regulation of transcriptomic pathways involved in platelet activation and aggregation.
These findings provide a potential biological framework for the differences in cardiovascular outcomes observed across GnRH-based therapies and further highlight the complex interplay between cancer treatment, thrombosis, and cardiovascular risk.
An important step toward better understanding how the choice of anticancer therapy may influence cardiovascular health in patients with prostate cancer.”
Title: Divergent Effects of GnRH Agonist and GnRH Antagonist Treatment on Platelet Activity and Transcriptome
Authors: Antonia Beitzen-Heineke, Matthew Siskin, Matthew Muller, Anshini Bhatt, Kathryn C. Hafertepe, Yuhe Xia, Minas Economides, David R. Wise, Jeffrey S. Berger
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 4, 2026, 18:57Connecting Haemophilia Centres, Certifying Treaters, and Improving National Data in Romania – EHC
-
Nov 4, 2026, 18:45Smitirupa Mishra: A Practical Guide to Coagulation Pathway Assessment and Laboratory Interpretation
-
Nov 4, 2026, 15:59Alessandra Bosch: A Successful Patient Day for the Bleeding Disorders Community in Zürich
-
Nov 4, 2026, 15:47Wolfgang Miesbach: Targeting Hepatic Endothelial Cells for Lentiviral Gene Therapy in Haemophilia A
-
Nov 4, 2026, 15:20Augustina Isioma Ikusemoro: Before You Transfuse, Think PBM
-
Nov 4, 2026, 14:23Advancing Hemophilia Care Through Global Research – WFH
-
Nov 4, 2026, 14:12Jean-Jacques Kiladjian: From JAK Inhibitor-Associated Skin Cancers to Laboratory Discovery
-
Nov 4, 2026, 13:59Rita Li: ASH 2026 Abstract Achievement Award for Gut Microbiome Research
-
Nov 4, 2026, 13:38Omid Seidizadeh: Improving Access to von Willebrand Disease Diagnosis and Treatment Across Europe